Effects of AS2586114, a soluble epoxide hydrolase inhibitor, on hyperlocomotion and prepulse inhibition deficits in mice after administration of phencyclidine

Abstract

Accumulating evidence suggests that soluble epoxide hydrolase (sEH) plays a key role in controlling levels of lipid signaling molecules, and that the potent sEH inhibitors may be potential therapeutic drugs for a number of diseases associated with metabolism of epoxyeicosatrienoic acids (EETs). This study was undertaken to examine whether the potent sEH inhibitor AS2586114 could attenuate behavioral abnormalities (e.g., hyperlocomotion and prepulse inhibition (PPI) deficits) in male ddY mice after a single administration of the N-methyl-D-aspartate (NMDA) receptor antagonist phencyclidine (PCP). A single oral administration of AS2586114 (10, 30, or 100mg/kg) attenuated the hyperlocomotion in mice after the administration of PCP (3.0mg/kg, s.c.), in a dose dependent manner. Furthermore, a single oral administration of AS2586114 (10, 30, or 100mg/kg) improved the PPI deficits in mice after the administration of PCP (3.0mg/kg, s.c.), in a dose dependent manner. In addition, the atypical antipsychotic drug clozapine (10mg/kg, p.o.) significantly attenuated hyperlocomotion and PPI deficits after the administration of PCP (3.0mg/kg, s.c.). In conclusion, this study suggests that AS2586114 may have antipsychotic activity in PCP models of schizophrenia. Therefore, it is likely that the sEH inhibitors may be potential therapeutic drugs for neuropsychiatric diseases such as schizophrenia.